Celularity (NASDAQ:CELU) Stock Price Up 3.3% – Should You Buy?

Celularity, Inc. (NASDAQ:CELU) shares rose 3.3% during trading on Wednesday . The stock traded as high as $0.8150 and last traded at $0.78. 23,376 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 133,087 shares. The stock had previously closed at $0.7550.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Celularity has a consensus rating of “Hold” and an average target price of $6.00.

Celularity Price Performance

The company has a market capitalization of $22.58 million, a price-to-earnings ratio of -0.23 and a beta of 0.54. The firm’s 50-day simple moving average is $0.79 and its two-hundred day simple moving average is $1.09.

Celularity (NASDAQ:CELU) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.85) earnings per share (EPS) for the quarter. The firm had revenue of $4.10 million for the quarter.

Hedge Funds Weigh In On Celularity

Several hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in Celularity during the fourth quarter worth $33,000. Acadian Asset Management LLC purchased a new position in shares of Celularity in the first quarter valued at $34,000. Jane Street Group LLC acquired a new position in shares of Celularity during the 4th quarter worth $46,000. Bank of America Corp DE raised its stake in shares of Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Celularity by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after buying an additional 20,876 shares in the last quarter. 19.02% of the stock is owned by institutional investors and hedge funds.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.